Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 4, 2008

Seaside Proffers $4.5M to Support Discovery Activities in Fragile X Syndrome at Vanderbilt

  • Seaside Therapeutics granted a $4.5 million collaborative research contract with Vanderbilt University Medical Center to discover compounds to suppress the manifestations of fragile X syndrome.

    Past research has indicated that excessive signaling through metabotropic glutamate receptor subtype 5 (mGluR5) may be responsible for the neurological and psychiatric consequences of fragile X syndrome.

    Seaside believes that selective inhibition of this receptor could reduce or eliminate the devastating effects of this disease. Scientists at Vanderbilt have identified more than 400 novel compounds belonging to multiple chemical classes that inhibit mGluR5.

    Vanderbilt researchers will use medicinal chemistry, molecular biology, pharmacology, and efficacy studies to discover and develop drug candidates. Seaside will contribute scientific and drug development expertise. The company will also select compounds from the collaboration to carry forward into clinical development.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »